Navigation Links
Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining
Date:12/1/2008

WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share for GlaxoSmithKline's Advair is declining in all lines of therapy for newly diagnosed asthma patients.

The new report entitled Treatment Algorithms in Asthma shows a reduction in Advair use in first-, second- and third-lines of therapy to 12.2 percent, 13.6 percent, and 14.6 percent, respectively when compared to the 2007 analysis that showed Advair was prescribed in 13.9 percent, 19.3 percent and 16.5 percent of first-, second- and third-line patients, respectively.

The decline in Advair's patient share is due to several factors: physicians' (particularly primary care physicians [PCPs]) increasing use of Merck's Singulair first-line, pushing Advair to later lines of therapy; specialists favoring newer once-daily inhaled corticosteroids (ICSs) with more favorable side-effect profiles in patients with less-severe disease prior to progressing to a long-acting beta2 agonist (LABA)/ICS combination; and physician movement towards using AstraZeneca's newly launched Symbicort as an alternative to Advair in later lines of therapy.

The report also finds that surveyed physicians will continue to use Singulair first-line regardless of March 2008 media reports linking the drug to behavior/mood changes and suicidality (suicidal thinking and behavior).

"The majority of pulmonologists, allergists and PCPs we surveyed told us that these media reports have had no effect on their treatment practice," added Dr. Westphal. "However, more surveyed allergists and PCPs told us that in the next two years they are likely to monitor their Singulair patients with increased vigilance, which likely reflects their treatment of a higher percentage of patients under the age of 18 compared with surveyed pulmonologists."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Natalia Morales                 Elizabeth Marshall
    Decision Resources              Decision Resources, Inc.
    781-296-2691                    781-296-2563
    nmorales@dresources.com         emarshall@dresources.com

'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novel Techniques Offers New Freedom to Patients with Parkinson's Disease, Epilepsy, Dystonia, and Tremor
2. Prescription for patient safety
3. Transfusing Anemic Cancer Patients Boosts Clot Risk
4. Major North American breakthrough for dialysis patients
5. Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, Were Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged
6. Singapore Caters to Middle East Medical Travelers with Arabic Version of Patients Beyond Borders-Singapore Edition
7. Pulmonary Hypertension Treated with Stem Cells : International Medical Team Announces Patient Results in Adult Stem Cell Clinical Study for Pulmonary Hypertension
8. Disclosure of medication can save a patients life
9. Steroid Inhalers Raise Pneumonia Risk for Lung Disease Patients
10. Doctors Receive Bonuses for Providing Optimal Care to Patients Through Bridges to Excellence
11. Transfusions increase clot risk in hospitalized cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
Breaking Medicine Technology: